The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
On May 21, BioMarin Pharmaceuticals announced positive results from its Phase 3 CANOPY-HCH-3 study for the dwarfism treatment VOXZOGO. These results led to a significant surge in the company's stock price, reflecting investor optimism about the potential effectiveness of the treatment.